Acutaas Chemicals (ACUTAAS) Stock Overview
Engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ACUTAAS from our risk checks.
ACUTAAS Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Acutaas Chemicals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,402.00 |
| 52 Week High | ₹1,445.00 |
| 52 Week Low | ₹672.58 |
| Beta | -0.066 |
| 1 Month Change | 20.13% |
| 3 Month Change | 19.19% |
| 1 Year Change | 105.68% |
| 3 Year Change | 177.73% |
| 5 Year Change | n/a |
| Change since IPO | 199.89% |
Recent News & Updates
Acutaas Chemicals Limited's (NSE:ACUTAAS) Earnings Haven't Escaped The Attention Of Investors
Aug 24
Korean Joint Venture And Battery Chemicals Will Expand Global Reach
Key Takeaways Expansion into high-growth technology sectors and international joint ventures positions the company for sustained revenue growth and long-term contract security. Focus on regulatory compliance, green initiatives, and higher-margin products is expected to drive profitability, margin improvement, and lasting competitive advantages.Acutaas Chemicals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 02Recent updates
Acutaas Chemicals Limited's (NSE:ACUTAAS) Earnings Haven't Escaped The Attention Of Investors
Aug 24Korean Joint Venture And Battery Chemicals Will Expand Global Reach
Key Takeaways Expansion into high-growth technology sectors and international joint ventures positions the company for sustained revenue growth and long-term contract security. Focus on regulatory compliance, green initiatives, and higher-margin products is expected to drive profitability, margin improvement, and lasting competitive advantages.Acutaas Chemicals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 02Here's Why We Think Acutaas Chemicals (NSE:ACUTAAS) Is Well Worth Watching
Jul 16There May Be Underlying Issues With The Quality Of Ami Organics' (NSE:AMIORG) Earnings
May 09Ami Organics Limited Just Recorded A 13% EPS Beat: Here's What Analysts Are Forecasting Next
May 07
CDMO Prospects Will Strengthen With New Ankleshwar Site And Semiconductor Expansion
Strategic developments in CDMO and semiconductor segments are set to drive significant revenue growth through innovative technology and market expansion.If EPS Growth Is Important To You, Ami Organics (NSE:AMIORG) Presents An Opportunity
Mar 04Ami Organics Limited (NSE:AMIORG) Looks Just Right With A 27% Price Jump
Feb 06Revenue Beat: Ami Organics Limited Beat Analyst Estimates By 11%
Jan 31Why Investors Shouldn't Be Surprised By Ami Organics Limited's (NSE:AMIORG) 30% Share Price Surge
Nov 07Market Participants Recognise Ami Organics Limited's (NSE:AMIORG) Revenues Pushing Shares 26% Higher
Sep 22We Think The Compensation For Ami Organics Limited's (NSE:AMIORG) CEO Looks About Right
Sep 14Ami Organics (NSE:AMIORG) Is Due To Pay A Dividend Of ₹3.00
Sep 02Ami Organics Limited (NSE:AMIORG) Not Lagging Industry On Growth Or Pricing
Jun 24Earnings Troubles May Signal Larger Issues for Ami Organics (NSE:AMIORG) Shareholders
May 21Ami Organics Limited Recorded A 7.8% Miss On Revenue: Analysts Are Revisiting Their Models
Feb 15We Think That There Are Some Issues For Ami Organics (NSE:AMIORG) Beyond Its Promising Earnings
May 24Analysts Have Made A Financial Statement On Ami Organics Limited's (NSE:AMIORG) Annual Report
May 20Ami Organics Limited's (NSE:AMIORG) Earnings Haven't Escaped The Attention Of Investors
Apr 01Shareholder Returns
| ACUTAAS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.1% | -0.9% | -1.5% |
| 1Y | 105.7% | -5.3% | -7.1% |
Return vs Industry: ACUTAAS exceeded the Indian Pharmaceuticals industry which returned -5.3% over the past year.
Return vs Market: ACUTAAS exceeded the Indian Market which returned -7.1% over the past year.
Price Volatility
| ACUTAAS volatility | |
|---|---|
| ACUTAAS Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 7.9% |
| 10% least volatile stocks in IN Market | 3.3% |
Stable Share Price: ACUTAAS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ACUTAAS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 676 | Naresh Patel | www.amiorganics.com |
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications, as well as in new chemical entities. It also provides specialty chemicals for use in agrochemicals, cosmetics, and polymers; and parabens and parabens formulation, salicylic acid, and other special chemicals that are used in cosmetics, dyes, polymers and agrochemical, animal foods, and personal care industries.
Acutaas Chemicals Limited Fundamentals Summary
| ACUTAAS fundamental statistics | |
|---|---|
| Market cap | ₹114.78b |
| Earnings (TTM) | ₹1.89b |
| Revenue (TTM) | ₹10.37b |
Is ACUTAAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACUTAAS income statement (TTM) | |
|---|---|
| Revenue | ₹10.37b |
| Cost of Revenue | ₹5.47b |
| Gross Profit | ₹4.91b |
| Other Expenses | ₹3.02b |
| Earnings | ₹1.89b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 23.09 |
| Gross Margin | 47.30% |
| Net Profit Margin | 18.22% |
| Debt/Equity Ratio | 1.0% |
How did ACUTAAS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/28 18:50 |
| End of Day Share Price | 2025/08/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Acutaas Chemicals Limited is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Ashwin Mehta | Ambit Capital |
| Nitin Bhasin | Ambit Capital |